The latest -Cancer Vaccines Markets -Report By Aarkstore

FOR IMMEDIATE RELEASE
(Free-Press-Release.com) January 23, 2012 -- Cancer Vaccines Markets
http://www.emarketreports.com/reports/Cancer-Vaccines-Markets-119447.html

Cancer vaccines have the potential to become a significant force in future cancer treatments. In 2010, Dendreon's Provenge became the first cancer vaccine approved by the FDA, generating renewed interest and support for this type of cancer immune therapy. Cancer vaccines can be divided into six main categories: antigen/adjuvant vaccines, DNA vaccines, vector-based vaccines, tumor cell vaccines, dendritic cell vaccines and anti-idiotype vaccines. This relatively new commercial market for cancer vaccines is poised to dramatically increase to over $7 billion by 2015. The purpose of this Company Publications report is to supply comprehensive information on the developing market for cancer vaccines. This study surveys almost all of the companies known to be marketing, manufacturing, or developing cancer vaccines in the world, providing in-depth analysis of the current and emerging technologies in the cancer vaccines market. Each company is extensively examined, with a section on its history, product line, business and marketing analysis, and a subjective commentary of the company's market position. Moreover, this report provides detailed discussions of cancer vaccines funding trends, intellectual property, market opportunities, research collaborations, partnership activities, regulatory issues and guidelines for establishing new ventures. Detailed tables and charts with sales forecasts and market share data are also included.
Table of Contents :
1. Overview 5
1.1 About this Report 5
1.2 Scope of the Report 6
1.3 Objectives 6
1.4 Methodology 6
1.5 Executive Summary 7

2. Overview of Cancer 9
2.1 Cancer Statistics 9
2.2 The Cost of Cancer 13
2.3 Cancers Being Targeted by Vaccine Therapies: Overview of Disease and Market 16

3. Introduction to Cancer Vaccines 24
3.1 Overview of the Types of Cancer Vaccines 24
3.2 Antigen/Adjuvant Vaccines 27
3.3 DNA Vaccines 33

INDEX OF FIGURES

Figure 2.1: Estimates of National Expenditures for Cancer Care in 2006 by Cancer Site 14
Figure 2.2: Person-Years of Life Lost (PYLL) in the U.S. Due to Cancer, Male, 2006 15
Figure 2.3: Person-Years of Life Lost (PYLL) in the U.S. Due to Cancer, Female, 2006 16
Figure 3.1: Antigen Presentation 25

INDEX OF TABLES

Table 2.1: Estimated New Cancer Cases and Deaths in the U.S. by Sex for all Cancer Sites, 2010 9
Table 2.2: Estimated New Cancer Cases and Deaths for Ten Leading Cancer Sites in the U.S. in 2010, by Sex 11

Table 2.3: Worldwide Number of New Cancer Cases and Deaths by Leading Cancer Sites and by Level of Economic Development, 2008 12
Table 2.4: Number of New Cancer Cases and Deaths by World Area, 2008 13
Table 2.5: Estimated Annual Costs of Cancer in the U.S. in Billions, 2008 14
Table 2.6: Cancer Vaccines in the Pipeline, by Cancer Type 17
Table 3.1: Infectious Agents Involved in Cancer 24

antigen vaccines     cancer     oncology     vaccines